IDEAYA and Roche will evaluate IDE892 plus RG6505 in MTAP-deleted, RAS-mutant pancreatic cancer, targeting a patient group with few treatment options.
Written By: Nikita Jha, BPharm
Reviewed By: Pharmacally Editorial Team
IDEAYA Biosciences and Roche have entered a clinical collaboration to evaluate IDE892, IDEAYA’s investigational PRMT5 inhibitor, in combination with Roche’s pan-RAS inhibitor RG6505 in patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC).
The study will assess the safety and efficacy of the combination in a molecularly defined subgroup of pancreatic cancer patients who currently have no approved targeted treatment options. IDEAYA will sponsor the trial, with Roche supplying RG6505. Both companies will jointly oversee the program while retaining commercial rights to their respective compounds.
Targeting a Genetic Subtype of PDAC
Pancreatic ductal adenocarcinoma remains one of the most lethal solid tumors, with limited treatment options and poor survival outcomes. MTAP deletion occurs in up to 40% of PDAC cases, and most MTAP-deleted tumors also harbor activating RAS mutations.
This genetic profile provides a strong biological rationale for combination therapy. PRMT5 inhibitors exploit vulnerabilities created by MTAP loss, while pan-RAS inhibitors block a key driver of pancreatic tumor growth.
IDE892 is a selective MTA-cooperative PRMT5 inhibitor that has demonstrated robust tumor regressions in preclinical MTAP-deleted cancer models. Pairing PRMT5 inhibition with RAS pathway blockade may deliver deeper and more durable anti-tumor responses than either approach alone.
Clinical Development Strategy
IDE892 is currently being evaluated in a Phase 1 dose-escalation study in patients with MTAP-deleted solid tumors. The Roche collaboration will expand development into combination treatment cohorts focused on MTAP-deleted, RAS-mutant PDAC.
The program reflects IDEAYA’s broader strategy of building combination regimens around its MTAP-deletion portfolio. In addition to the Roche collaboration, the company plans to evaluate IDE892 with IDE397, its proprietary MAT2A inhibitor, in non-small cell lung cancer and other MTAP-deleted solid tumors.
According to IDEAYA President and Chief Executive Officer Yujiro S. Hata, the collaboration supports the company’s strategy of advancing biologically rational combination therapies for MTAP-deleted cancers while addressing a major unmet need in pancreatic cancer.
Path Forward
Beyond the initial doublet study, the collaboration framework allows for potential evaluation of a triplet regimen combining IDE892, RG6505, and IDE397, subject to mutual agreement between the companies.
The study will provide an early test of whether simultaneous targeting of PRMT5 and RAS signaling can improve outcomes in MTAP-deleted pancreatic cancer. If successful, the approach could establish a new targeted treatment strategy for up to 40% of PDAC patients whose tumors carry MTAP deletions and who currently lack approved precision medicine options.
Reference
About the Writer
Nikita Jha, BPharm (LinkedIn) a pharmacy graduate specializing in medical writing, with a strong ability to interpret complex medical and regulatory information and translate it into clear, accurate, and evidence-based healthcare content. Known for her attention to detail and precision, she focuses on delivering high-quality scientific communication that supports drug safety and informed decision-making.